We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
Read MoreHide Full Article
Key Takeaways
AbbVie's Q2 neuroscience revenues are projected to rise 15% year over year to $3.09 billion.
ABBV is expected to see higher sales from Botox Therapeutic, Vraylar, Ubrelvy and Qulipta.
AbbVie expects Vyalev to build on strong momentum after projected Q2 sales of $238 million.
AbbVie (ABBV - Free Report) is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued strength of the company’s blockbuster immunology franchise, the performance of its neuroscience portfolio is also expected to be closely watched. In the first quarter, neuroscience revenues rose 26% year over year to nearly $2.88 billion, reflecting broad-based momentum across its key brands.
The Zacks Consensus Estimate for second-quarter 2026 neuroscience revenues is pegged at $3.09 billion, indicating 15% year-over-year growth. Higher sales of Botox Therapeutic and depression drug Vraylar are likely to have contributed to growth during the quarter. Sales of the oral migraine drugs Ubrelvy and Qulipta likely benefited from continued market share gains across their approved indications.
Vyalev is also expected to be a key contributor to the neuroscience franchise, having demonstrated strong commercial momentum since its U.S. launch last year. After generating $201 million from the drug’s sales in first-quarter 2026, the Zacks Consensus Estimate projects second-quarter sales of $238 million. Management had previously reiterated that Vyalev is on track to achieve blockbuster status this year. Another quarter of strong uptake would further strengthen the drug's position as an important long-term growth driver for AbbVie's neuroscience business.
Other Players in the Neuroscience Space
AbbVie faces competition from large-cap biotech/pharmaceutical companies in the market, which include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for Alzheimer's disease. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.02 times forward earnings, lower than its industry’s average of 18.23.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.30 to $14.23, while the 2027 estimate has fallen from $16.30 to $16.12 over the past 30 days.
View the Zacks #1 Rank List
Image: Shutterstock
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
Key Takeaways
AbbVie (ABBV - Free Report) is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued strength of the company’s blockbuster immunology franchise, the performance of its neuroscience portfolio is also expected to be closely watched. In the first quarter, neuroscience revenues rose 26% year over year to nearly $2.88 billion, reflecting broad-based momentum across its key brands.
The Zacks Consensus Estimate for second-quarter 2026 neuroscience revenues is pegged at $3.09 billion, indicating 15% year-over-year growth. Higher sales of Botox Therapeutic and depression drug Vraylar are likely to have contributed to growth during the quarter. Sales of the oral migraine drugs Ubrelvy and Qulipta likely benefited from continued market share gains across their approved indications.
Vyalev is also expected to be a key contributor to the neuroscience franchise, having demonstrated strong commercial momentum since its U.S. launch last year. After generating $201 million from the drug’s sales in first-quarter 2026, the Zacks Consensus Estimate projects second-quarter sales of $238 million. Management had previously reiterated that Vyalev is on track to achieve blockbuster status this year. Another quarter of strong uptake would further strengthen the drug's position as an important long-term growth driver for AbbVie's neuroscience business.
Other Players in the Neuroscience Space
AbbVie faces competition from large-cap biotech/pharmaceutical companies in the market, which include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for Alzheimer's disease. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.02 times forward earnings, lower than its industry’s average of 18.23.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.30 to $14.23, while the 2027 estimate has fallen from $16.30 to $16.12 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.